0000929638-25-001925.txt : 20250515 0000929638-25-001925.hdr.sgml : 20250515 20250515172050 ACCESSION NUMBER: 0000929638-25-001925 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91717 FILM NUMBER: 25955867 BUSINESS ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 BUSINESS PHONE: (302) 467-1280 MAIL ADDRESS: STREET 1: 175 INNOVATION BOULEVARD CITY: WILMINGTON STATE: DE ZIP: 19805 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Vaddi Krishna CENTRAL INDEX KEY: 0001824633 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SCHEDULE 13G/A MAIL ADDRESS: STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED STREET 2: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0001193125-21-038413 0001824633 XXXXXXXX LIVE 5 Common Stock, par value $0.0001 per share 03/31/2025 0001678660 Prelude Therapeutics Inc 74065P101 175 INNOVATION BOULEVARD WILMINGTON DE 19805 Rule 13d-1(d) Vaddi Krishna X1 6397839 0 6397839 0 6397839 N 13.8 IN (1) The aggregate amount beneficially owned by the Reporting Person consists of (i) 4,728,081 shares of voting common stock beneficially owned directly by the Reporting Person, consisting of (a) 1,999,296 shares of voting common stock and (b) 2,728,785 shares of voting common stock underlying stock options that are exercisable within 60 days of March 31, 2025, (ii) 142,553 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. (2) The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficially owned by the Reporting Person and an aggregate of 43,604,202 shares of voting common stock outstanding as of March 31, 2025, as reported by the Issuer to the Reporting Person, plus the number of shares underlying stock options held by the Reporting Person that are exercisable within 60 days of March 31, 2025, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person. Prelude Therapeutics Inc 175 INNOVATION BOULEVARD, WILMINGTON, Delaware, 19805 Krishna Vaddi (the "Reporting Person") The address of the principal business office of the Reporting Person is: c/o Prelude Therapeutics Incorporated 175 Innovation Boulevard Wilmington, Delaware 19805 United States Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. Y Y Y Y Y Y Vaddi Krishna /s/ Krishna Vaddi 05/15/2025